Persistence of bactericidal antibodies following, booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial (vol 35, pg 395, 2017)


Por: Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ and European Men B Vaccine Study Group

Publicada: 31 may 2017
Resumen:


Filiaciones:
Iro MA:
 Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK

Snape MD:
 Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK

Voysey M:
 Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK

 Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK

Jawad S:
 Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK

Finn A:
 Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK

Heath PT:
 St Georges Vaccine Institute, St George's, University of London, London, UK

Bona G:
 Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy

Esposito S:
 Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

:
 Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain

Prymula R:
 Charles University Prague, School of Medicine Hradec Kralove, Czech Republic

Odueyungbo A:
 Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA

Toneatto D:
 GSK Vaccines S.r.l., Siena, Italy

Dull P:
 Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA

Pollard AJ:
 Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK
ISSN: 13588745





Vaccine
Editorial
Elsevier BV, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Países Bajos
Tipo de documento: Correction
Volumen: 35 Número: 24
Páginas: 3279-3279
WOS Id: 000405881000018
ID de PubMed: 28483197
imagen Green Accepted, hybrid, Green Published

FULL TEXT

imagen Published Version CC BY

MÉTRICAS